Pacira Pharma (PCRX) Tops Q2 EPS by 3c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Pacira Pharma (PCRX) Tops Q2 EPS by 3c, Revenues Beat

Pacira Pharma (PCRX) Reports Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

August 5, 2020 7:39 AM EDT

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full results its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) administered via transversus abdominis plane (TAP) field block in patients undergoing Cesarean section (C-section) have been published in Anesthesia and Analgesia. In this study, EXPAREL achieved its primary endpoint with a... More

Pacira Pharma (PCRX) Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients

August 4, 2020 7:35 AM EDT

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include single-dose infiltration to provide postsurgical analgesia in children aged six and over. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is March 22, 2021.

The sNDA is based on the... More